VLP Biotech
Privately held biotechnology company focused on development of epitope-focused virus‑like particle (VLP) vaccine candidates. The organization develops and optimizes hybrid VLPs based on hepadnavirus core proteins, performs recombinant protein design and production using bacterial expression, and conducts preclinical immunogenicity testing and animal challenge studies across multiple infectious‑disease indications.
Industries
Nr. of Employees
small (1-50)
VLP Biotech
3030 Bunker Hill Street, Suite 205, San Diego, CA 92109 USA
Patents
Products
Custom recombinant proteins for antibody production
Engineered recombinant proteins and hybrid VLP constructs designed to present selected epitopes for induction of antibody responses.
Custom recombinant proteins for antibody production
Engineered recombinant proteins and hybrid VLP constructs designed to present selected epitopes for induction of antibody responses.
Services
Design of custom recombinant proteins to present target epitopes for antibody production.
Expression of recombinant constructs (primarily in bacterial systems) and downstream purification workflows for VLPs and vaccine constructs.
Preclinical immunogenicity testing including animal challenge studies to assess protective efficacy and antibody responses.
Design of custom recombinant proteins to present target epitopes for antibody production.
Expression of recombinant constructs (primarily in bacterial systems) and downstream purification workflows for VLPs and vaccine constructs.
Preclinical immunogenicity testing including animal challenge studies to assess protective efficacy and antibody responses.
Expertise Areas
- Vaccine platform development
- Recombinant protein engineering
- Preclinical vaccine evaluation and animal challenge models
- Process development for biologics expression and purification
Key Technologies
- Virus-like particle (VLP) platforms
- Hybrid epitope-display VLP engineering
- Combinatorial VLP design
- Recombinant protein expression
News & Updates
Awarded a subcontract to develop epitope‑focused malaria vaccine candidates to support the USAID Malaria Vaccine Development Program.
Received Phase I STTR funding to develop a MRSA vaccine candidate with collaborators at the University of Michigan.
Received Phase I SBIR funding to further develop an RSV vaccine candidate shown to protect rodents in challenge studies.
Peer‑reviewed publication reporting development of P. falciparum and P. vivax epitope‑focused VLPs that elicited sterile immunity in a mouse model (PLOS One).
Acquired vaccine-related patents from an affiliated research institute to strengthen IP position.
Awarded a subcontract to develop epitope‑focused malaria vaccine candidates to support the USAID Malaria Vaccine Development Program.
Received Phase I STTR funding to develop a MRSA vaccine candidate with collaborators at the University of Michigan.
Received Phase I SBIR funding to further develop an RSV vaccine candidate shown to protect rodents in challenge studies.
Peer‑reviewed publication reporting development of P. falciparum and P. vivax epitope‑focused VLPs that elicited sterile immunity in a mouse model (PLOS One).
Acquired vaccine-related patents from an affiliated research institute to strengthen IP position.